Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

Translated title of the contribution: Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.

E. Kneppers, B. van der Holt, M.J. Kersten, S. Zweegman, E. Meijer, G. Huls, J.J. Cornelissen, J.J. Janssen, C. Huisman, P.B. Cornelisse, C.P. Bruijnen, M.E. Emmelot, P. Sonneveld, H.M. Lokhorst, T. Mutis, M.C. Minnema

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionLenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Original languageUndefined/Unknown
Pages (from-to)2413-2419
Number of pages7
JournalBlood
Volume118
Issue number9
Publication statusPublished - 2011

Cite this